WASHINGTON (Reuters) - Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc’s lung drug Spiriva compared with placebo, the U.S. Food and Drug Administration said on Tuesday.
WASHINGTON (Reuters) - Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc’s lung drug Spiriva compared with placebo, the U.S. Food and Drug Administration said on Tuesday.
